Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct;132(4):e139-e142.
doi: 10.1016/j.oooo.2021.06.019. Epub 2021 Jul 19.

Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report

Affiliations
Case Reports

Stevens-Johnson syndrome post second dose of Pfizer COVID-19 vaccine: a case report

Mohamed Omar Elboraey et al. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 Oct.

Abstract

Coronavirus disease 2019 (COVID-19) began in December 2019 and has affected millions of people all over the world. Respiratory illness in the form of severe pneumonia, in addition to multiorgan failure and death, is the clinical spectrum of COVID-19. Although there are no specific therapeutic agents for COVID-19 infection, the COVID-19 vaccine reduces morbidity and mortality associated with COVID-19 infection and is generally well tolerated. We report one potential complication of the Pfizer COVID-19 vaccine: a known case of Stevens-Johnson syndrome (SJS) that occurred after the second dose of the Pfizer COVID-19 vaccine alone without exposure to any other drug. Despite the initial severe adverse reaction, the patient showed a full recovery. Although SJS can be associated with COVID-19 vaccination, it is rare, and the benefits of receiving the vaccination outweigh the potential harms.

PubMed Disclaimer

Figures

Fig 1
Fig. 1
Large, deep-red bullae at retromolar area.
Fig 2
Fig. 2
Large oral ulcerations at labial mucosa with yellow crust at lower lip.
Fig 3
Fig. 3
Multiple large oral ulcerations at buccal mucosa.

References

    1. Łoboda J, Dudzik A, Chomyszyn-Gajewska M. Stevens-Johnson syndrom and toxic epidermal necrolysis–based on literature. Przegl Lek. 2015;72:35–37. - PubMed
    1. Tristani-Firouzi P, Petersena MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47:548–552. - PubMed
    1. Prins C, Kerdel FA, Padilla S, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003;139:26–32. - PubMed
    1. Patel P, Gandhi AM, Desai CK, Desai M, Dikshit RK. An analysis of drug induced Stevens-Johnson syndrome. Indian J Med Res. 2012;136:1051–1053. - PMC - PubMed
    1. Kumar R, Das A, Das S. Management of Stevens-Johnson syndrome-toxic epidermal necrolysis: looking beyond guidelines. Indian J Dermatol. 2018;63:117–124. - PMC - PubMed

Publication types

Substances